Document:

<PAGE>

                                                                   Exhibit 10.14

                             MANUFACTURING AGREEMENT

                                 by and between

                                NPS ALLELIX CORP.

                                       and

                             SYNCO BIO PARTNERS B.V.

<PAGE>

THIS MANUFACTURING AGREEMENT (the "Agreement") is made and entered into June 12,
2001 ("Effective Date"), by and between:

NPS ALLELIX Corp. ("NPS"), with its principal place of business at 6850 Goreway
Drive, Mississauga, Ontario, Canada L4V I V7,

and

SynCo Bio Partners B.V. ("SYNCO"), with its registered offices at Paasheuvelweg
30, 1105 BJ Amsterdam, The Netherlands,

Background

-     NPS has developed the proprietary product ALX1-11, recombinant human
      parathyroid hormone ("rhPTH"), and the process to manufacture it and is
      currently (or will soon be) in Phase III Clinical Trials with rhPTH
      worldwide (including the United States, Canada, Latin America, Europe and
      India);

-     SYNCO operates as a biopharmaceutical service provider and has experience
      with the manufacture of rhPTH and SYNCO desires to manufacture rhPTH for
      NPS in accordance with NPS' requirements in order to facilitate NPS'
      Clinical Trials and NPS' early commercial launch of rhPTH after NDA
      approval in the U.S. and elsewhere;

-     NPS desires to have SYNCO conduct such manufacturing activities to
      facilitate the Clinical Trials and early commercial launch of rhPTH;

-     NPS and SYNCO (the "Parties") have signed a Letter of Intent on December
      15, 2000 and Parties now desire to reach a final agreement on the
      manufacture of bulk quantities of rhPTH for clinical trials and early
      commercial use;

-     The Parties have agreed that SYNCO will manufacture rhPTH subject to the
      provisions set forth hereinafter;

NOW, THEREFORE, in consideration of the premises, the mutual covenants, terms
and conditions hereinafter set forth, THE PARTIES AGREE AS FOLLOWS:

ARTICLE 1- DEFINITIONS

For the purpose of this Agreement the following terms shall be defined as:

1.1   "Affiliated Company" means a corporation or other entity which: (a) is
      Controlled directly or indirectly by a Party; (b) Controls directly or
      indirectly a Party; or (c) is under common Control with a Party. Control
      herein means fifty percent (50%) or more of the voting stock or equity, or
      other comparable interest.

                                                                               2
<PAGE>

1.2   "Batch" means GMP Grade rhPTH from SYNCO's production thereof in a 1500
      liter fermenter as set out in the Specifications and in particular
      MF-MFS-PTH-0000/MF-MFS-PTH-2500 (as referenced in Appendix A).

1.3   "Batch Production Records" (BPRs) means completed written records
      providing the history of a Batch of rhPTH required to be kept by the
      European Guide to Good Manufacturing Practices for Medicinal Products, the
      U.S. Code of Federal Regulations, and ICH Guideline Q7A.

1.4   "Campaign" means the manufacture of thirty (30) Batches of rhPTH and any
      Excess Batches ordered by NPS pursuant to Article 5.3 in a given calendar
      year, namely 2002, 2003 or 2004.

1.5   "Clinical Trials" means the use of the product rhPTH pursuant to any
      protocols which have received or do receive FDA approval or approval by
      the counterpart European or other Agency during the term of this Agreement
      for the purpose of conducting clinical studies to determine the safety,
      efficacy or other characteristics of rhPTH.

1.6   "Confidential Information" means any information and data disclosed by
      Parties in writing and designated confidential or, if disclosed orally,
      confirmed in writing and designated confidential within thirty (30) days
      after such disclosure.

1.7   "European GMP" means the current European Guide for Good Manufacturing
      Practices for Medicinal Products.

1.8   "Excess Batch" means each Batch manufactured by SYNCO pursuant to Article
      5.3 in excess of a Campaign of thirty (30) Batches of rhPTH in a given
      year.

1.9   "FDA" means the United States Food and Drug Administration or any
      successor agency having similar jurisdiction.

1.10  "GMP Grade" means rhPTH that has been produced in accordance with the
      Regulatory Standards and the Specifications.

1.11  "Material" means working cell banks and analytical standards as described
      in Appendix B. Appendix B will be updated if SYNCO requires further
      Material from NPS pursuant to Article 3.1(i).

1.12  "NDA" means a New Drug Application as defined by the FDA for marketing of
      rhPTH.

1.13  "NDA approval" means approval of a New Drug Application by FDA for the
      marketing of rhPTH.

1.14  "Parties" and "Party" means SYNCO and NPS and SYNCO or NPS, respectively,
      as the context may require.

                                                                               3
<PAGE>

1.15  "Plant" means SYNCO's manufacturing facility which will be used to
      manufacture, package and store rhPTH and all required documentation as
      provided for in this Agreement and is located at Paasheuvelweg 30, 1105 BJ
      Amsterdam, The Netherlands, licensed for manufacturing under number
      101972A.

1.16  "Pre-Approval Inspection" means inspection of the Plant by FDA or
      corresponding European representatives in conjunction with the filing of
      an NDA or corresponding European application which may include among other
      things: verifying the accuracy and completeness of the
      manufacturing-related information submitted in the NDA or corresponding
      European application; evaluating manufacturing controls upon which
      information provided in the NDA or corresponding European application is
      based; evaluating U.S. cGMP compliance or European GMP compliance; and
      collecting samples of GMP Grade rhPTH.

1.17  "Regulatory Standards" means (i) the Plant license requirements, (ii)
      European GMP and U.S. cGMP regulations applicable to the manufacturing,
      storage and handling of rhPTH at the Plant and (iii) any standards of any
      governmental authority that apply to the Plant or SYNCO's manufacturing,
      storage and handling of rhPTH.

1.18  "rhPTH" means recombinant human parathyroid hormone (1-84) ALX1-11 as an
      active pharmaceutical ingredient (API).

1.19  "Specifications" means all specifications as described in Appendix A,
      reference standards, control and test documentation, validation records,
      Batch Production Records, deviation reports, quality control, storage,
      packaging and labelling specifications and other information related to
      rhPTH arising from U.S. cGMP and European GMP and SYNCO's performance
      under this Agreement and as approved of by NPS.

1.20  "U.S. cGMP" means current Good Manufacturing Practices as described in the
      U.S. Code of Federal Regulations.

1.21  "Yield" means grams of rhPTH bulk drug substance produced per Batch as
      indicated in the Batch Production Records approved by SYNCO'S Quality
      Assurance pursuant to Article 6.5.

ARTICLE 2 - SCOPE OF THE AGREEMENT

2.1   The scope of this Agreement is to manufacture bulk quantities of rhPTH for
      use in Clinical Trials and as early commercial product. Parties
      acknowledge that SYNCO is presently not licensed under the United States
      Food and Drug Administration as a commercial manufacturer; and NPS has
      presently no product licence for rhPTH issued by the United States Food
      and Drug Administration or any other regulatory body. In view of this
      scope, SYNCO will be responsible for obtaining and complying with those
      requirements and licences as set forth in Article 5. In particular, SYNCO
      will file and maintain Drug Master Files as required by the U.S. FDA and
      European counterpart, to provide NPS necessary and sufficient information
      and data to complete Section 7 of an NDA (including the chemistry,
      formulation, manufacturing and quality control information) and pass a
      Pre-Approval Inspection as required by the U.S. FDA. It is understood that
      rhPTH is classified as a 'drug' by the U.S. FDA and that SYNCO is
      considered a manufacturer of bulk active pharmaceutical ingredient under
      the U.S. FDA Regulations.

                                                                               4
<PAGE>

2.2   Parties agree that the manufacture and delivery of rhPTH under this
      Agreement will be performed by SYNCO in two (2) phases:

      Phase I: Early Manufacture of rhPTH in 2001

      Phase II: Manufacture of rhPTH in three (3) Campaigns in each of 2002,
                2003 and 2004

      Phase I and Phase II will be conducted in accordance with the timelines
      and deliverables set out in Appendix D.

2.3   The following Appendices are attached hereto and are incorporated in and
      are deemed to be an integral part of this Agreement.

      Appendix A - Specifications
      Appendix B - Material
      Appendix C - Equipment Owned by NPS
      Appendix D - Timelines and Deliverables

ARTICLE 3 - OBLIGATIONS OF THE PARTIES

3.1   Obligations of NPS. NPS shall at NPS' cost:

            (i)   NPS has provided at the Effective Date of the Agreement a
                  written description (QC-PCP-PTH-0046) which is the basis of
                  the Specifications as set out in Appendix A. If NPS desires a
                  change to the Specifications as set out in Appendix A, it is
                  NPS' obligation to provide the change in writing to SYNCO and
                  to negotiate with SYNCO for inclusion of this change into
                  Appendix A. Such changes are subject to negotiation and
                  written approval by SYNCO as set out in paragraph 3.2(x).

            (ii)  Furnish SYNCO, free of charge, with Material in sufficient
                  quantities, for the sole purpose of use by SYNCO in its
                  manufacture of rhPTH in Batch quantities in both Phase I and
                  Phase II. The Material will remain the exclusive property of
                  NPS. At the Effective Date of the Agreement, NPS has furnished
                  the Material to SYNCO in sufficient quantities to manufacture
                  the Batches in Phase I and part of Phase II. NPS shall provide
                  further Material to SYNCO on a timely basis for Phase II as
                  required. NPS' Quality Assurance will release all Material and
                  will supply SYNCO with a Certificate of Analysis based on 5
                  on-going tests for Viability and Tetracycline according to
                  QC-SPC-PTH-1547 (to be superseded by an equivalent document
                  re-written by SYNCO and approved by NPS).

                                                                               5
<PAGE>

            (iii) Provide the equipment as set out in Appendix C, which
                  equipment will remain the property of NPS for the duration of
                  the Agreement and on termination of this Agreement. At the
                  Effective Date of the Agreement NPS has provided to SYNCO and
                  SYNCO has received possession and accepted the condition of
                  the equipment in Appendix C.

            (iv)  Accept delivery and perform required testing and evaluation in
                  a timely manner (other than what SYNCO is responsible for) for
                  release of each Batch of rhPTH manufactured by SYNCO as set
                  out in Article 6.6.

            (v)   Perform in a timely manner its obligations reflected in or to
                  be reflected in and pursuant to the provisions hereof and of
                  Appendix D.

            (vi)  NPS shall review and when acceptable notify SYNCO of NPS'
                  approval of all documents and changes thereto written by SYNCO
                  specific for rhPTH production.

            (vii) NPS shall retain title in the equipment in Appendix C; the
                  Material; and Batches which NPS has paid for in full pursuant
                  to Article 8.2. NPS shall hold appropriate insurance for the
                  equipment in Appendix C; the Material; and Batches which NPS
                  has paid for pursuant to Article 8.2.

           (viii) NPS is responsible for registering its title under the
                  appropriate legislation to the equipment in Appendix C and the
                  Material. NPS is responsible for registering a security
                  interest in the Batches which NPS has partially paid for
                  pursuant to Article 8.2.

      3.2   Obligations of SYNCO. SYNCO shall be responsible for the activities
            identified in this Agreement, in particular as identified in Article
            6, and in addition thereto, and more particularly, SYNCO shall:

            (i)   Not transfer the Material to any third party and, at the
                  request of NPS, return to NPS any unused quantities of the
                  Material at the termination of this Agreement.

            (ii)  Confirm that the Material is satisfactory for the manufacture
                  of rhPTH. SYNCO will notify NPS prior to production of each
                  Batch if the Material is not satisfactory and can not be used
                  for the manufacture of GMP Grade rhPTH in accordance with this
                  Agreement. SYNCO will maintain records of usage of the
                  Material, and will inform NPS of needs for additional
                  quantities or changes in characteristics thereof in a timely
                  manner.

            (iii) Purchase all raw materials required for the manufacture of
                  rhPTH other than the Material.

                                                                               6
<PAGE>

            (iv)  Perform quality control and assurance release procedures for
                  the release of rhPTH in accordance with Article 6.

            (v)   Provide all other equipment, other than that provided by NPS
                  as set out in Appendix C, necessary for the manufacture,
                  testing, storage, release, and delivery of rhPTH in accordance
                  with this Agreement. All of the equipment, including the
                  equipment in Appendix C shall be validated and maintained by
                  SYNCO for the manufacture of rhPTH in accordance with this
                  Agreement and as provided for in the Specifications. The
                  equipment in Appendix C will be used only for production of
                  rhPTH, unless otherwise agreed upon NPS, under this Agreement
                  and will be returned to NPS by SYNCO within six (6) months
                  following termination of this Agreement.

            (vi)  Perform the manufacturing process for the product Batches of
                  rhPTH as outlined in MF-MFS-PTH-2500 and in accordance with
                  all other Specifications in Appendix A and the Regulatory
                  Standards.

            (vii) Prepare and maintain the Batch Production Records and related
                  control, distribution and other records required to comply
                  with Specifications.

           (viii) Perform quality control and assurance review of process raw
                  materials and in-process materials, and Batches.

            (ix)  Obtain other materials including consumable materials required
                  for the conduct of this Agreement.

            (x)   All documents written by SYNCO specific for rhPTH production
                  shall be in the English language. Any changes to these
                  documents shall follow a change of control procedure in
                  accordance with European GMP and U.S. cGMP. In addition SYNCO
                  shall provide timely the MF-MFS-PTH-0000 Specification in
                  Appendix A which will be equivalent to MF-MFS-PTH-2500
                  Specification. SYNCO shall consider and use best efforts to
                  come to an agreement with NPS for inclusion of any changes to
                  Appendix A, as suggested by NPS pursuant to paragraph 3.1(i).
                  Any change must be approved of in writing by SYNCO.

            (xi)  Ensure that the manufacture of Batches of rhPTH complies with
                  all process requirements including quality in-process control
                  limits of acceptance as found in MF-MFS-PTH-2500 (and as
                  superseded by MF-MFS-PTH-0000), set out in Appendix A.

                                                                               7
<PAGE>

            (xii) Provide and maintain appropriate personnel, facilities,
                  equipment, the Plant, and support documents to carry out the
                  manufacture of Batches of GMP Grade rhPTH as required by this
                  Agreement.

           (xiii) Be responsible for all actions and activities at the Plant
                  required for U.S. cGMP and European GMP compliance.

            (xiv) Dispatch all rhPTH to NPS in a timely manner and ensure such
                  rhPTH and other deliverables are done according to NPS'
                  instructions during delivery and until received by NPS.

            (xv)  Store the manufactured rhPTH in compliance with European GMP
                  and U.S. cGMP until released to NPS at NPS' request.

            (xvi) Perform its obligations in a timely manner and pursuant to the
                  schedule in Appendix D.

           (xvii) SYNCO shall co-operate fully with NPS in transferring, among
                  other things: know-how; equipment; technology; information;
                  Material; biological material; and documentation at NPS'
                  request to facilitate the further manufacture of rhPTH at a
                  third party manufacturing facility.

          (xviii) Synco shall retain title in the work-in-progress and to any
                  Batch which has not yet been paid for in full by NPS pursuant
                  to Article 8.2. SYNCO shall hold appropriate insurance for the
                  work-in-progress and Batches for which it retains title.

            (xix) SYNCO will co-operate with NPS as reasonably required by NPS
                  in registering NPS' title under the appropriate legislation to
                  the equipment in Appendix C and the Material and in
                  registering NPS' security interest in the Batches which NPS
                  has partially paid for pursuant to Article 8.2.

ARTICLE 4 - PHASE I: EARLY MANUFACTURE OF rhPTH

4.1   Phase I will comprise the manufacturing of ten (10) Batches of GMP Grade
      rhPTH in 2001 by SYNCO in accordance with this Agreement. Phase I will end
      when SYNCO has manufactured the ten (10) Batches of GMP Grade rhPTH and
      NPS' Quality Assurance has released for clinical use or early commercial
      sale these ten (10) Batches pursuant to Article 6.6.

4.2   For each Batch manufactured during Phase I, SYNCO will charge NPS a price
      of two hundred and two thousand nine hundred and ninety two (202992) Euro.

4.3   Except as provided for in this paragraph, SYNCO warrants that during Phase
      I, Batches of rhPTH will be GMP Grade and SYNCO will assume all
      obligations under this Agreement in respect thereto. SYNCO will not
      warrant a certain Yield for the ten (10) Batches.

                                                                               8
<PAGE>

4.4   A Future Guaranteed Average Yield will be established by the parties for
      Phase II. The Future Guaranteed Average Yield, unless otherwise agreed to
      by the parties, shall be:

      (i)   for Campaign 1, Phase II:
            (a)   the average of the Yield per Batch over all Batches of rhPTH
                  manufactured during Phase I and released by NPS and which
                  Batches are not subject to deviations which NPS believes
                  affects Yield; or
            (b)   40 grams/Batch if (a) is less then 40 grams/Batch;
      (ii)  for Campaigns 2 and 3, Phase II:
            (a)   the average of the Yield per Batch over all Batches of rhPTH
                  manufactured during Phase I and released by NPS and which
                  Batches are not subject to deviations which NPS believes
                  affects Yield; or
            (b)   if requested by NPS, the average of the Yield per Batch over
                  the first ten (10) Batches manufactured in Campaign 1 of Phase
                  II in 2002 and released by NPS and which first ten (10)
                  Batches are not subject to deviations which NPS believes
                  affects Yield; or
            (c)   40 grams/Batch if (a) and (b) are each less then 40
                  grams/Batch.

ARTICLE 5 - PHASE II: MANUFACTURE OF rhPTH

5.1   Phase II will start after Phase I is completed pursuant to Article 4.1 or
      earlier upon request of the parties. During Phase II, SYNCO warrants that
      the Batches of rhPTH will be GMP Grade and SYNCO assumes all other
      obligations in respect thereto, including guaranteeing an average Yield
      per Batch of the manufacturing process (as established according to
      Article 4.4), as calculated over thirty (30) Batches manufactured during
      Phase II which are released by NPS in accordance with Article 6.6.

5.2   SYNCO will manufacture Batches of rhPTH on a Campaign basis with a minimum
      fixed quantity of thirty (30) Batches. If SYNCO fails to meet the total
      yield based on thirty (30) times the Guaranteed Average Yield, NPS may
      request that SYNCO at its own expense manufacture further Batches to make
      up the shortfall. In the alternative, if SYNCO fails to meet the total
      yield based on thirty (30) times the Guaranteed Average Yield, and at NPS'
      request, NPS will receive a discount equal to the number of grams SYNCO
      manufactured below the total yield multiplied by a price per gram based on
      the price per Batch (pursuant to Article 4.2) divided by the Guaranteed
      Average Yield.

5.3   NPS will give SYNCO three (3) months advance notice in writing prior to
      January 1 of the years 2002, 2003, or 2004 should NPS require Excess
      Batches. NPS may order up to a maximum of twenty (20) Excess Batches or
      the equivalent yield (based on the Future Guaranteed Average Yield) in any
      or all of years 2002, 2003 and 2004. Based on available capacity, SYNCO
      will begin production of excess quantity of rhPTH ordered, 9 within nine
      (9) months of receipt of the notice in writing ordering such Excess
      Batches, and will perform such production in a manner calculated not to
      effect any change in delivery of the first thirty (30) Batches in a
      Campaign.

                                                                               9
<PAGE>

5.4   A price per gram of rhPTH for delivery of Batches and/or for Excess
      Batches will be established in good faith negotiations between the Parties
      prior to each Campaign in Phase II and based on, among other things, price
      per Batch as established in Article 4.2 and the Future Guaranteed Average
      Yield as established in Article 4.4.

5.5   For each Batch manufactured during Phase II, SYNCO will charge NPS a price
      of two hundred and two thousand nine hundred ninety-two (202992) Euro
      (price level year 2001), excluding price indices as described in Article
      8.3. If NPS decides to order the equivalent grams of rhPTH (based on the
      Future Guaranteed Average Yield) instead of the thirty (30) batches, NPS
      will pay the price per gram as established according to Article 5.4,
      excluding price indices as described in Article 8.3.

5.6   The manufacturing, release and delivery of GMP Grade rhPTH for each
      Campaign shall be done according to the schedule in Appendix D.

ARTICLE 6 - REGULATORY AFFAIRS AND QUALITY ASSURANCE

6.1   SYNCO will exercise all reasonable skill, care and diligence customary in
      the industry in the performance of its duties under this Agreement and in
      accordance with the requirements of European GMP and U.S. cGMP. SYNCO
      shall obtain and maintain all permits required under Dutch legislation in
      order to manufacture rhPTH. SYNCO will inform NPS of all permits filed
      under Dutch legislation or otherwise and their status with respect to
      approval.

6.2   The parties acknowledge that the manufacture of rhPTH in accordance with
      this Agreement and the Specifications is believed to correspond to GMP
      requirements in all material respects. However, NPS will cooperate with
      SYNCO, in obtaining full and complete compliance with the relevant U.S.
      Code of Federal Regulations by identifying with the aid of a Consultant
      identified by NPS and reasonably acceptable to SYNCO, (which Consultant
      shall be hired by SYNCO and paid for by NPS under terms of employment and
      compensation reasonably acceptable to NPS) those areas where modification
      or improvement should be considered by SYNCO intended to maintain and
      improve GMP compliance for the Plant or manufacture of rhPTH, including,
      among others: Standard Operating Procedures; methods; documentation
      practices; rhPTH product manufacture, storage, labelling and packaging;
      and operations. SYNCO agrees to seek, perform, and implement all such
      recommendations of the Consultant as shall be reasonably requested by NPS.

6.3   SYNCO will file and maintain for its facility in Amsterdam a Plant Master
      File ("PMF") with the Health Protection Branch in Canada and with the
      regulatory agency in The Netherlands. SYNCO will also file and maintain
      Drug Master Files (DMFs) as required by the U.S. FDA. The timelines for
      these filings is set out in Appendix D. For regulatory purposes, including
      the filing of an NDA, NPS shall have rights to refer 10 to the PMF and
      DMFs and to similar documents and SYNCO will give NPS access to
      information in the PMF, DMFs and to similar documents which are necessary
      to complete regulatory documentation and are related to rhPTH and its
      manufacture in the Plant.

                                                                              10
<PAGE>

6.4   Subject to reasonable prior notice, NPS or its designated representatives
      may audit and inspect the Plant for the purpose of reviewing manufacturing
      of rhPTH and quality assurance standards and for determining compliance
      with European GMP and U.S. cGMP at reasonable times during the term of
      this Agreement, to the extent that such inspections relate solely to
      SYNCO's manufacture of rhPTH for NPS and subject to SYNCO's obligations of
      confidentiality to third parties. SYNCO will provide full cooperation for
      these inspections.

6.5   SYNCO shall review and approve all Batch Production Records for Quality
      Assurance and shall investigate all deviations on such Batch Production
      Records within sixty (60) days of production. SYNCO's Quality Assurance
      department shall also ensure that SYNCO's Plant and manufacturing
      operations for rhPTH are in compliance with the Specifications, Regulatory
      Standards, U.S. cGMP, European GMP and SYNCO's SOPs and with any other
      applicable law or regulation in effect during the time of manufacture of
      rhPTH.

6.6   SYNCO will supply NPS with copies of all Batch Production Records,
      deviation reports and test results (including out of specification test
      results) for each Batch produced at the time of invoice. NPS will have
      final responsibility for confirming Quality Assurance and for the release
      of each Batch of GMP Grade rhPTH manufactured by SYNCO for use in Clinical
      Trials or commercial use.

6.7   SYNCO will retain raw material samples as required under U.S. cGMP and
      European GMP. Initially, SYNCO will release raw materials after identity
      testing and obtaining a certificate of analysis. However, in accordance
      with U.S. cGMP, Vendor Qualification specific to the raw materials used to
      manufacture rhPTH pursuant to this Agreement or full specification testing
      according to raw material specifications as set out in Appendix A, in
      particular in MF-MSF-PTH-2500, will be conducted. Appendix D sets out the
      timeline for Vendor Qualification or full specification testing.

6.8   SYNCO will obtain NPS' written approval, not to be unreasonably withheld,
      in advance of any modifications to the raw materials, facility, utilities,
      process, procedures, production or Plant equipment used in the manufacture
      of rhPTH. None of these modifications will be inconsistent with
      maintaining compliance with the Specifications or to the applicable law or
      regulations to the extent required under this Agreement for producing GMP
      Grade rhPTH.

6.9   SYNCO will retain complete, accurate and authentic documents on
      manufacturing data, test records, Batch Production Records, deviation
      reports, standard operating procedures and raw material samples and any
      other documents, samples and information as required by U.S. cGMP and
      European GMP and permit NPS access to all originals of such material for
      the term appropriate for compliance with U.S. cGMP and European GMP. All
      original manufacturing data, test records, Batch Production Records and
      other materials required by U.S. cGMP and European GMP for the production
      of rhPTH, will be delivered promptly upon NPS request. Parties recognize
      that this transfer of documentation to NPS may be in conflict with the
      provisions of article 9.1 of European GMP. Therefore, Parties agree that
      the transfer will only be effected if the Pharmaceutical Inspection in The
      Netherlands would relieve SYNCO from its duties under this article 9.1 of
      European GMP.

                                                                              11
<PAGE>

6.10  SYNCO will cooperate fully with recognised regulatory authorities of the
      European Community (EC) and with the FDA during inspections related to the
      manufacture of rhPTH in the Plant. The expected timeline for Pre-Approval
      Inspection is set out in Appendix D. SYNCO will notify NPS immediately of
      any such inspections and will make arrangements, where feasible, for NPS
      to attend any such inspections.

ARTICLE 7 - WARRANTIES AND LIABILITY

7.1   In addition to other warranties provided for in this Agreement, SYNCO
      warrants that:

      (a)   SYNCO has and will maintain all permits under Dutch legislation in
            order to manufacture rhPTH;

      (b)   The Material, when received, will be stored in accordance with the
            relevant Specifications, U.S. cGMP and European GMP;

      (c)   rhPTH produced by SYNCO under this Agreement will comply with the
            Specifications and Regulatory Standards, it will be GMP Grade, will
            have been manufactured, packed, stored and delivered in compliance
            with this Agreement and applicable laws, orders and regulations,
            including U.S. cGMP and European GMP, and that the Plant, equipment
            and personnel used to produce rhPTH will be at all times qualified
            to manufacture GMP Grade rhPTH;

      (d)   For the term of this Agreement, the Plant will be operated and
            maintained in accordance with all applicable laws, rules, orders and
            regulations, including U.S. cGMP and European GMP;

      (e)   SYNCO agrees that it will not carry on activities in the Plant that
            could reasonably prevent rhPTH from being manufactured, packed and
            stored in accordance with applicable laws, rules and regulations,
            including U.S. cGMP and European GMP;

      (f)   The manufacturing, release and delivery of GMP Grade rhPTH for each
            Campaign shall be done according to the schedule in Appendix D,
            unless otherwise agreed to by the Parties.

      EXCEPT AS OTHERWISE EXPRESSLY PROVIDED HEREIN, SYNCO MAKES NO WARRANTIES
      EXPRESS OR IMPLIED AND EXPRESSLY DISCLAIMS WARRANTIES OF FITNESS FOR A
      PARTICULAR PURPOSE, AND SYNCO SHALL NOT BE LIABLE FOR INCIDENTAL OR
      CONSEQUENTIAL DAMAGES IN ANY CASE OF NONCONFORMITY. NEITHER PARTY SHALL BE
      LIABLE TO THE OTHER PARTY FOR INCIDENTAL OR CONSEQUENTIAL DAMAGES ARISING
      FROM ANY ALLEGED OR ACTUAL BREACH OF THIS AGREEMENT.

                                                                              12
<PAGE>

7.2   SYNCO shall promptly replace, free of charge, any quantity of rhPTH which
      is not GMP Grade provided NPS notifies SYNCO in writing upon discovery of
      the defect or non-conformity within a period of sixty (60) days after
      receipt of all documentation and information from SYNCO by NPS pursuant to
      Article 6.5 and Article 6.6, and provided NPS allows SYNCO to evaluate the
      claim and to test the said quantity of rhPTH within a reasonable period of
      time, not to exceed sixty (60) days. For rhPTH which is determined not to
      be GMP Grade (either by agreement of the parties or by an independent
      qualified expert pursuant to Article 7.3), such rhPTH shall be replaced
      during the current or next Campaign, and in no event later than the
      Campaign in 2004, with GMP Grade rhPTH. If such rhPTH is not replaced with
      GMP Grade rhPTH as provided for in this paragraph, NPS shall receive a
      full refund for any payment made for such rhPTH pursuant to Article 8.1.
      (Refund shall be paid by SYNCO within thirty (30) days of the date of an
      invoice from NPS.)

7.3   If the Parties disagree as to whether or not the said quantity of rhPTH is
      GMP Grade, then a qualified independent party, acceptable to both parties,
      will determine if the quantity of rhPTH is GMP Grade. The resulting
      determination will be final and binding on SYNCO and NPS. SYNCO will bear
      the cost of the third party evaluation if the testing demonstrates that
      the rhPTH is not GMP Grade. If the rhPTH is determined to be GMP Grade,
      then NPS shall bear all costs of the third party evaluation.

7.4   NPS will indemnify and hold SYNCO and its Affiliated Companies harmless
      from and against any and all losses, claims, damages or liabilities
      (including but not limited to reasonable attorney's fees), arising from
      (a) any use, including clinical trials, or sale by NPS or any third party
      of any rhPTH supplied by SYNCO hereunder; (b) any allegation by any third
      party of infringement of its intellectual property rights by reason of the
      manufacture, use or sale of rhPTH by SYNCO, NPS or any third party; (c)
      breach by NPS of its representations, warranties or covenants under this
      Agreement; or (d) any negligence or intentional wrongdoing of NPS.
      However, NPS shall not indemnify SYNCO for such losses, claims, damages or
      liabilities that are due to the negligent or reckless activities or
      omissions of SYNCO, its officers, employees or agents, or as a result of,
      in respect of, or arising out of any breach of any representation,
      warranty or guarantee of SYNCO in connection with this Agreement.

7.5   If any claim is made for which a Party may seek indemnification from the
      other, the Party seeking indemnity shall promptly notify the other Party
      of the nature and basis of such claims and amounts thereof, to the extent
      known. In the event any action, suit or proceeding is brought against a
      Party with respect to which the other Party may have liability hereunder,
      the other Party may, at its option and at its own expense, elect to assume
      the defence of any such action, suit or proceeding itself, and if it does
      not so elect, the Party having the action, suit or proceeding brought
      against it will assume the defence thereof. Neither Party shall make any
      settlement of claims without the written consent of the other party, which
      consent shall not be unreasonably withheld.

                                                                              13
<PAGE>

ARTICLE 8 - PAYMENTS

8.1   For the manufacture and delivery of GMP Grade rhPTH, NPS shall pay SYNCO
      as specified in Article 4 and Article 5. For each Batch of rhPTH or grams
      of rhPTH manufactured by SYNCO, SYNCO shall invoice NPS after SYNCO's
      Quality Assurance has approved of the Batch Production Records and
      investigated all deviations as set out in Article 6.5. SYNCO will supply
      NPS with copies of all Batch Production Records, deviation reports and
      test results (including out of specification test results) for each Batch
      produced at the time of invoice.

8.2   Invoices will be in Euro's and all payments to SYNCO shall be made in
      Euro's. All payments shall be made within thirty (30) days of the date of
      the invoice. Payments not made when due shall bear interest at the Dutch
      bank rate. Upon mutual agreement payments can be made in U.S. Dollars. As
      of the Effective Date of this Agreement, NPS has paid SYNCO four hundred
      seventeen thousand eight hundred fifty five (417855) Euros which payment
      shall be credited against future monies owing to SYNCO by NPS under this
      Agreement.

8.3   Prices, including the price to be calculated under Article 5.4, will be
      updated on an annual basis beginning January 1, 2002. The adjustment
      factor will be the official National Price Index Factor prior to the
      calendar year for which the price adjustment will become effective, as
      published by the Government of the Netherlands plus three (3) percent.

8.4   Liability For Payment. Termination of this Agreement under this Article,
      shall not release any Party from any liability for payment accrued or
      accruing to the other Party prior to the termination date.

ARTICLE 9 - CONFIDENTIALITY AND INTELLECTUAL PROPERTY

9.1   A Party receiving Confidential Information (including, without limitation,
      Specifications, information related to the Plant and other data designated
      as confidential in writing by either Party) from the other or developing
      such information hereunder shall not disclose such information to any
      third party or any Affiliated Company and shall keep it in strict
      confidence, use it solely for the purposes authorized under this Agreement
      during the term hereof and shall not disclose such information, for a
      period extending nine (9) years following termination, except as follows:

      (a)   to the extent such information is or becomes general public
            knowledge through no fault of the recipient Party; or

      (b)   to the extent such information can be shown by contemporaneous
            documentation of the recipient Party to have been in its possession
            prior to receipt thereof hereunder; or

      (c)   to the extent such information is received by the recipient Party
            from a third 14 party without any breach of an obligation by the
            disclosing Party; or

                                                                              14
<PAGE>

      (d)   to the extent required by law, by local authorities for regulatory
            purposes or is necessary to perform its obligations under this
            Agreement, in which case, the recipient Party may disclose the
            information if the recipient Party gives the other Party prior
            notice of such disclosure and an opportunity to comment upon the
            content of the disclosure. However, SYNCO shall have the right, at
            all times and without the obligation to give notice to NPS, to use
            information related to its Plant for its own business purposes and
            NPS shall have the right, at all times and without the obligation to
            give notice to SYNCO, to use the information related to rhPTH for
            its own business purposes.

9.2   NPS hereby grants to SYNCO a royalty-free, non-transferable, non-exclusive
      license, without the rights to sub-license, under all patent rights and
      know-how owned or controlled by NPS, required to manufacture rhPTH for NPS
      in accordance with this Agreement for the term of this Agreement.

9.3   SYNCO agrees to give NPS a royalty-free, non-exclusive license on any
      ideas, innovations or inventions arising from this Agreement which are
      related to or useful to the manufacture of rhPTH and to negotiate in good
      faith an exclusive license at NPS' request. This non-exclusive license can
      be sub-licensed.

9.4   This Agreement supersedes all other agreements, express or implied,
      between the parties concerning confidentiality.

ARTICLE 10 - TERM OF AGREEMENT AND TERMINATION

10.1  Term. This Agreement shall upon signature by both Parties become effective
      on the Date of Agreement and remain in effect until December 31, 2005,
      unless extended by agreement of the Parties for an additional term.

10.2  Termination. A Party shall have the right without prejudice to any rights
      exercisable, damages accrued or claims for damages or other relief, to
      terminate this Agreement by written notice to the other Party upon
      occurrence of any of the following events:

      (a)   if such Party becomes insolvent in that liabilities exceed assets,
            is adjudged bankrupt or insolvent, applies for judicial or extra
            judicial settlement with its creditors, makes an assignment for the
            benefit of its creditors, voluntarily files for bankruptcy or has a
            receiver or trustee (or the like) in bankruptcy appointed over its
            business, property or assets, or if a Party becomes the subject of
            liquidation or dissolution (except for reconstruction purposes such
            as mergers etc.) or involuntary bankruptcy proceedings or otherwise
            discontinues business;

      (b)   if such Party breaches any material term or condition of this
            Agreement and the defaulting Party, having received sixty (60) days
            written notice of such default from the Party asserting the breach,
            fails to fully cure such breach within sixty (60) days of receipt of
            such notice from the Party asserting the breach.

                                                                              15
<PAGE>

10.3  Liability For Payment. Termination of this Agreement under this Article,
      shall not release any Party from any liability for payment accrued or
      accruing to the other Party prior to the termination date.

10.4  Survival of Termination.

      (a)   Article 9.3 shall survive termination or expiration of this
            Agreement (as the case may be) and shall remain in full force and
            effect.

      (b)   The provisions of Articles 7.4, 7.5, 8.1, 8.4, 12.6, 12.8 and 12.10
            shall survive termination or expiration of this Agreement (as the
            case may be) and shall remain in full force and effect for five (5)
            years after termination or expiration of this Agreement.

      (c)   The provisions of Articles 3.2(xii, xiii, xiv, xviii), 6.3, 6.4,
            6.6, 6.7, 6.9 and 6.10 shall survive termination or expiration of
            this Agreement (as the case may be) and shall remain in full force
            and effect for two (2) years after termination or expiration of this
            Agreement.

ARTICLE 11- NOTICES

11.1  Any notices or other communications to be served on or sent to either
      Party shall be sufficiently served or sent if sent by fax and confirmed by
      registered return receipt prepaid mail within twenty-four (24) hours after
      dispatch of the fax to such Party at its address as set out below or such
      other address as such Party may notify in writing to the other Party from
      time to time.

      Notices to SYNCO shall be to:
      -----------------------------

      Managing Director
      SynCo Bio Partners B.V.
      Paasheuvelweg 30
      1105 BJ Amsterdam
      The Netherlands
      Attn: Mic N. Hamers, Ph.D.

      Notices to NPS shall be to:
      ---------------------------

      NPS Allelix Corp.
      6850 Goreway Drive
      Mississauga, Ontario L4V 1V7
      Canada
      Attn: Rick Wilcocks

                                                                              16
<PAGE>

        With a copy to:

        NPS Pharmaceuticals, Inc.
        420 Chipeta Way
        Salt Lake City, UT 84108
        Attn: Thomas B. Marriott, Ph.D.

        or to such other address as a Party may designate.

ARTICLE 12 - ADDITIONAL TERMS

12.1  Force Majeure. A Party shall not be held liable to the other for any delay
      in performance or non-performance of that Party directly or indirectly
      caused by reason of force majeure including, but not limited to,
      industrial disputes, strike, lockouts, riots, mobs, fires, floods, or
      other natural disasters, wars declared or undeclared, civil strife,
      embargo, lack or failure of transport facilities, currency restrictions,
      or events caused by reason of laws, regulations or orders by any
      government, governmental agency or instrumentality or by any other
      supervening circumstances beyond the control of either Party. Provided,
      however, that the Party affected shall: give prompt written notice to the
      other Party of the date of commencement of the force majeure, the nature
      thereof, and expected duration; and shall use its best efforts to avoid or
      remove the force majeure to the extent it is able to do so; and shall make
      up, continue on and complete performance when such cause is removed to the
      extent it is able to do so. Either Party has the right to terminate the
      Agreement with immediate effect, upon written notice to the other Party,
      should the force majeure continue after three (3) months following the
      first notification. For the purpose of this Agreement, termination of the
      clinical development of the rhPTH will not be considered force majeure.

12.2  Non-Waiver. The failure by any Party at any time to enforce any of the
      terms or provisions or conditions of this Agreement or exercise any right
      hereunder shall not constitute a waiver of the same or affect the validity
      of this Agreement or any part hereof, or that Party's rights thereafter to
      enforce or exercise the same. No waiver by a Party shall be valid or
      binding, except if in writing and signed by a duly authorized
      representative of the waiving Party.

12.3  Severability. In case one or more of the provisions contained in this
      Agreement shall, for any reason, be held invalid, illegal or unenforceable
      in any respect, such holding shall not affect any other provisions of this
      Agreement, but this Agreement shall be construed by limiting such
      provision to such extent as would nearly as possible reflect the intent,
      purpose and economic effect of such provision, or, if such is not
      possible, by deleting such provision from this Agreement, provided that
      the remaining provisions reflect the intent of the Parties, as evidenced
      by this Agreement as a whole.

12.4  Assignment. This Agreement is deemed personal to SYNCO. Neither Party
      shall sell, assign, transfer, encumber or otherwise dispose of its
      interest in this Agreement or any of its rights or obligations, except to
      an Affiliated Company, without the prior written consent of the other,
      which consent shall not unreasonably be withheld.

                                                                              17
<PAGE>

12.5  Enurement. This Agreement is binding on all successors and permitted
      assignees.

12.6  Non-competition. SYNCO will not manufacture rhPTH or any related compound
      (for this purpose: a compound that (i) competes with rhPTH for binding to
      the parathyroid hormone receptor as defined in the rat osteosarcoma (UMR
      106 cell line) based receptor binding assay and (ii) shares at least
      eighty percent (80%) homology with rhPTH (eighty-four (84) amino acids) or
      with the thirty four (34) amino acids N-terminal fragment of rhPTH) for
      itself or any third party before January 1, 2009, except if this Agreement
      is terminated by SYNCO under Article 10.2.

12.7  Captions. All titles and captions in this Agreement are for convenience
      only and shall not affect its interpretation.

12.8  Law and Arbitration. This Agreement shall be governed, construed and
      interpreted by the laws of the Netherlands. The Parties agree that all
      disputes between them arising out of or relating to this Agreement shall
      be settled by arbitration in accordance with the Rules of Conciliation and
      Arbitration of the International Chamber of Commerce by three arbitrators
      appointed in accordance with such Rules. The Parties shall not be entitled
      to terminate this Agreement during the pendency of any claim or dispute
      between them under this Agreement. The arbitration proceedings shall take
      place in Amsterdam, The Netherlands and shall be conducted in the English
      language. Judgement on the award may be issued by and enforced by any
      court of competent jurisdiction.

12.9  Entire Understanding. This Agreement (including appendices) is the entire
      understanding and agreement between the Parties relating to the subject
      matter hereof and supersedes (except as provided herein) any and all prior
      arrangements, understandings, and agreements between the Parties whether
      written or oral relating thereto. No amendments, changes, or modifications
      of the terms of this Agreement shall be valid or binding unless made in
      writing and signed by the duly authorized representatives of each Party.

12.10 Independent Status of Parties. Each Party is an independent trader acting
      in its own name and for its own account. Neither Party has any authority
      to act as an agent or representative of the other, or to contract in the
      name of, or create or assume any obligation against, or otherwise legally
      bind, the other Party in any way for any purpose, unless agreed separately
      in writing. All costs and expenses connected with each Party's activities
      and performance under this Agreement unless otherwise separately agreed or
      provided for in this Agreement are to be borne solely by the Party
      incurring such costs and expenses.

12.11 Duplicate Originals. This Agreement is executed in duplicate originals one
      being retained by each Party hereto.

                                                                              18
<PAGE>

      IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be
executed by their duly authorized representatives:

SYNCO BIO PARTNERS B.V.                    NPS ALLELIX CORP.

/s/ Mic N. Hamers                          /s/ Thomas B. Marriott
-----------------------------              -----------------------------
Mic N. Hamers, Ph.D.                       Thomas B. Marriott, Ph.D.
Managing Director                          Vice President, Development Research

                                                                              19<PAGE>

                                                                   Exhibit 10.15

                      ADDENDUM TO MANUFACTURING AGREEMENT

      This ADDENDUM made effective as of the 26 October, 2001, is between SYNCO
BIO PARTNERS B.V. (hereinafter "SYNCO") having an office at Paasheuvelweg
30, 1105 BJ Amsterdam Zuidoost, the Netherlands and NPS ALLELIX CORP., a
corporation incorporated under the laws of Ontario and having as office at 6850
Goreway Drive, Mississauga, Ontario Canada L4V 1V7 (hereinafter "NPS ALLELIX").

      WHEREAS, SYNCO and NPS ALLELIX entered into a Manufacturing
Agreement, effective as of 17 May, 2001 (hereafter the "Agreement"); and

      WHEREAS, both NPS ALLELIX and SYNCO wish to continue the Agreement but in
addition NPS ALLELIX now desires SYNCO to prepare a PTH Standard for NPS ALLELIX
and SYNCO wishes to produce such PTH Standard for NPS ALLELIX.

      THEREFORE, the parties agree to the following addendum to the Agreement;

1.    SYNCO shall produce a minimum of 4,500 vials of PTH Standard ("Vials of
      PTH Standard") in accordance with Appendix D. Each vial shall contain
      0.3ml of a 2.1mg PTH/ml solution. The Vials of PTH Standard shal1 be
      prepared according to European GMP Guidelines. Batch Production Records
      shal1 be prepared by SYNCO and approved by NPS ALLELIX.

2.    NPS ALLELIX shall pay SYNCO 31,500 Euros for the Vials of PTH Standard. On
      release of the Vials of PTH Standard by SYNCO to NPS ALLELIX, SYNCO shall
      invoice NPS ALLELIX in the amount of 31,500 Euros and NPS ALLELIX shall
      pay within thirty (30) days of such invoice.

3.    The Vials of PTH Standard shall be filled by week 47 and tested as set
      out in Appendix D. SYNCO shall release the Batch Documents together with
      the Vials of PTH Standard to NPS within ten (10) weeks of filling the
      Vials of PTH Standard.

<PAGE>

4.    Unless explicitly altered by the Addendum, a1l terms of the Agreement as
      applicable shall apply to the production and release of the Vials of PTH
      Standard. Furthermore, this Addendum is not intended to alter any of the
      rights or obligations set out in the Agreement in the production of PTH
      under the Agreement.

         IN WITNESS WHEREOF, the parties hereto have caused this Addendum to be
executed by their duly authorized representatives

SYNCO BIO PARTNERS B.V.                    NPS ALLELIX CORP.

/s/ Mic N. Hamers                          /s/ Thomas B. Marriott
---------------------------                -----------------------------
Mic N. Hamers, Ph.D.                       Thomas B. Marriott, Ph.D.
Managing Director                          Vice President, Development Research

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00052-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00052-of-00352.parquet"}]]